Affiliation:
1. Department of Microbiology, School of Medicine, Infectious Diseases Research Center, Gonabad University of Medical Sciences, Gonabad, Iran.
Abstract
Non-small cell lung cancer (NSCLC) ranks among the top contributors to cancer-related mortality globally. Recently, immunotherapy, particularly immune checkpoint inhibitors, has achieved groundbreaking progress in the treatment of NSCLC, significantly improving patient outcomes. This review explored the mechanisms of immunotherapy in NSCLC, with a focus on the roles of the PD-1/PD-L1 and CTLA-4 pathways. The discussion then shifted toward the currently approved and investigational immunotherapy drugs, including Nivolumab, Pembrolizumab, and Atezolizumab. Subsection sections review the recent progress of research on novel immunotherapeutic agents and biomarkers and discuss the side effects of immunotherapy. Finally, we provide an outlook on the prospects of NSCLC immunotherapy, exploring how precision medicine and personalized treatment strategies can further enhance therapeutic efficacy. In conclusion, immunotherapy for NSCLC has made significant advancements in both mechanistic research and clinical application.
Publisher
Asian Medical Press Limited
Reference51 articles.
1. Jonna S, Subramaniam DS: Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update. Discov Med 2019, 27(148): 167-170.
2. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK: Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 2014, 14(8): 535-546.
3. Passaro A, Mok TSK, Attili I, Wu YL, Tsuboi M, de Marinis F, Peters S: Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review. JAMA Oncol 2023, 9(8): 1124-1131.
4. Rossi A, Di Maio M: Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles. Expert Rev Anticancer Ther 2016, 16(6): 653-660.
5. Yu Y, Zeng D, Ou Q, Liu S, Li A, Chen Y, Lin D, Gao Q, Zhou H, Liao W et al: Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. JAMA Netw Open 2019, 2(7): e196879.